Hyperviscosity Syndrome in Rheumatoid Arthritis

To the Editor:

Hyperviscosity syndrome (HVS) is a life-threatening condition often occurring as a complication of Waldenström macroglobulinemia (WM) but rarely in the context of rheumatic disease. Given its rarity, diagnosis can be delayed, leading to greater morbidity. Our interest was sparked by a recent experience with a patient with rheumatoid arthritis (RA) who developed epistaxis with progressively worsening dyspnea, confusion, and visual deficits culminating in hospitalization due to HVS1. As HVS is uncommon in the era of biologic medications, we conducted a systematic review (Supplementary Figure 1, available from the authors on request) to define factors that predispose to HVS and describe outcomes of previous treatment approaches. We identified 25 cases of hyperviscosity attributed to RA.

The most common presenting features for HVS included bleeding diathesis (e.g., epistaxis, gastrointestinal hemorrhage, gingival bleeding), heart failure (dyspnea and/or pedal edema), neurologic symptoms (dizziness, syncope, confusion), and constitutional symptoms (Table 1). RA developed years before HVS (7.9 ± 7.4 yrs) but was the presenting manifestation in 3 cases. Synovitis was often active at time of diagnosis, and use of disease-modifying antirheumatic drugs prior to HVS was rare (n = 6). Retinopathy with venous distention was common and correlated with neurologic deficits. Adenopathy and/or splenomegaly occurred in over half the patients, and rheumatoid nodules were common. Features of rheumatoid vasculitis—scleritis/episcleritis, skin ulcers, and periungual infaracts—were described in 7 cases, with only half associated with cryoglobulins.

Rheumatoid factor (RF) was positive in all cases of HVS, with 83% (n = 18) having a titer > 1:5120. Mean serum viscosity was 10.7 ± 12.5 cP. Polyclonal hypergamaglobulinemia was common, involving IgG, IgA, and IgM, though these were distinctly lower than levels associated with HVS in WM and multiple myeloma. Anemia was present in 90%, and neutropenia in 47%. One-third of the latter had known or suspected Felty syndrome; none had large granular lymphocytic leukemia or lymphoma. Only 1 patient had a monoclonal gammopathy. Antinuclear antibody was often positive with a homologous staining pattern in titers > 1:640. Few cases reported antibodies to extractable nuclear antigens. Anti-dsDNA antibodies were reported in 2 patients. Sicca was documented in 4 cases, including 2 with abnormal Schirmer test.

Plasmapheresis was performed in 83% (19 of 23; Supplementary Table 1, available from the authors on request). The overall recurrence rate for HVS was 43% (10 of 23) at 11.3 ± 14.7 months. After plasmapheresis, HVS recurred as early as 1 month and as late as 4 years. Plasmapheresis monotherapy was effective in 2 of 4. Addition of methotrexate with hydroxychloroquine was effective at preventing recurrence for 1 patient with HVS. Rituximab (RTX) was successful in 1 patient and is often used for HVS related to WM.

HVS in RA can occur with levels of Ig much lower than in WM. In RA, this has been attributed in part to aggregations of Ig, termed intermediate complexes, which have a sedimentation coefficient between that of monomeric IgG and pentameric IgM. Different intermediate complexes have been associated with hyperviscosity, including either IgG or IgM RF aggregating with polyclonal IgG. In SJögren syndrome, the degree of hyperviscosity correlates directly with the titer of the RF in addition to disease activity. Erythrocyte aggregation is also an important feature of HVS in RA.
RA and is related to Ig and fibrinogen levels, though this may not be fully appreciated with serum viscosity.

HVS is a rare complication of RA, especially in this era of effective disease-modifying therapy. This should be considered in patients with long-standing, seropositive RA presenting with bleeding diathesis, dyspnea and/or altered mentation, especially those with active synovitis, high RF, marked erythrocyte sedimentation rate elevation, anemia, and/or hypergamma-globulinemia. Early identification and treatment are important to prevent complications, and diagnosis is confirmed by checking viscosity level. In patients with HVS, plasmapheresis followed by further immunosuppression is recommended. CYC has the most data available; however, there is a paucity of data for HVS maintenance therapy in RA. The relationship to RF titer and intermediate complexes supports the use of RTX, and this has been effective in our patient.

John B. Miller, MD
Alan N. Baer, MD
1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

The research reported in this publication was supported in part by the Cupid Foundation to JBM.

The authors declare no conflicts of interest.

Address correspondence to Dr. J.B. Miller, Instructor of Medicine, 5200 Eastern Ave., Mason F. Lord Building Center Tower, Suite 4100, Baltimore, MD 21224, USA. Email: JMill237@jhmi.edu.

REFERENCES